Condition category
Infections and Infestations
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information



Primary contact

Prof Graham Foster


Contact details

Clinical Research Centre
The Royal London Hospital
2 Newark Street
E1 2AT
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

A double blind, placebo controlled study to evaluate the safety and immunogenicity of escalating doses of 10^8 colony forming units (CFU), 10^9 CFU and 10^10 CFU of M04NM11 in patients who have chronic hepatitis B infection


Study hypothesis

To show that M04NM11 is safe, compared to placebo, when given in escalating doses to patients with chronic hepatitis B virus.

Ethics approval

Ethics approval has been obtained from the following Ethics Committees:
1. Multicentre Research Ethics Committee for Scotland on the 15/11/2006, ref: 06/MRE10/37
2. Clinical Centre Kragujevac Ethics Committee on the 18/01/2007, ref: 01-460/22.01
3. Clinical Centre of Serbia Ethics Committee on the 25/01/2007, ref: 39/10
4. Clinical Centre Novi Sud Ethics Committee on the 31/01/2007, ref: 00-01/13

Study design

Multicentre double-blind randomised dose escalation study

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Chronic hepatitis B virus


Patients will visit the clinic a total of 20 times over the one year treatment period.

M04NM11 or placebo will be administered orally in escalating doses of 10^8 CFU, 10^9 CFU and 10^10 CFU within each patient if well tolerated. Patients will receive up to six doses at 28 day intervals over a five month period, with a six month follow-up period.

During this time, they will be required to provide blood and urine samples for assessment of safety and efficacy. A stool sample will be taken at the end of the trial.

Intervention type



Not Specified

Drug names


Primary outcome measures

1. The incidence of clinically significant changes in serum biochemistry and haematology tests, particularly elevations of ALT or bilirubin, or prolongation of PT
2. The incidence of adverse events, including flu-like symptoms, attributable to the investigational product
3. The incidence of serious adverse events attributable to the investigational product

The primary outcome measures will be at screening; on days 3, 7, 14 and 28 after the first dose; days 7, 14 and 28 after the second dose and days 14 and 28 after subsequent doses. Following receipt of the final dose, patients will be followed up for a further 20 weeks up to day 308.

Secondary outcome measures

1. The proportion of patients in each group who experience a decrease in HBV DNA load of greater than or equal to 2 log10, or a reduction to less than 10 x 4 copies/mL, maintained until day 168 (28 days after the final dose)
2. The proportion of patients in groups 1 and 2 who become HBeAg negative at any study visit before day 168 (28 days after the final dose)
3. The proportion of patients in each group who were negative for anti-HBe at baseline, who have anti-HBe at day 168 (28 days after the final dose), or if patients were anti-HBe positive at baseline the proportion who have a four-fold increase in anti-HBe titre at day 168
4. The proportion of patients in each group with normal ALT levels by day 168
5. The proportion of patients in each group who demonstrate a significant change in the frequency of HBV specific interferon gamma producing T cells determined by enzyme-linked immunosorbent spot (ELISPOT) assay or by intracellular cytokine staining
6. The proportion of patients who maintain a treatment effect in the follow up period as demonstrated by maintenance of the reduction in HBV DNA load achieved during the treatment period, maintenance of HBeAg negative status or conversion to HBeAg negative status between days 196 and 308 (two to six months after the last dose)

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Participating patients must be over 18 years of age, either sex
2. Have been hepatitis B surface antigen (HBsAg) positive for at least six months
3. A detailed medical history demonstrating stable alanine aminotransferase (ALT), prothrombin time (PT) and serum bilirubin and a liver biopsy in the previous 24 months
4. Patients will be stratified and recruited according to hepatitis B 'e' antigen (HBeAg) status and viral deoxyribonucleic acid (DNA) load

Participant type


Age group




Target number of participants

Up to 45 patients

Participant exclusion criteria

1. Have any hypersensitivity to the investigational medicinal product (IMP)
2. Are hepatitis C virus (HCV) or hepatitis D virus (HDV) positive
3. Are receiving or have received medication for their hepatitis B in the previous 12 months
4. Have evidence of hepatic decompensation, cirrhosis or ALT greater than 5.1 x upper limit of normal (ULN), PT greater than 1.25 x ULN or total bilirubin greater than 1.5 x ULN
5. Immuno-suppression or close contact with immuno-suppressed people

Recruitment start date


Recruitment end date



Countries of recruitment

Serbia, United Kingdom

Trial participating centre

Clinical Research Centre
E1 2AT
United Kingdom

Sponsor information


Emergent Product Development UK Ltd (UK)

Sponsor details

540 - 545 Eskdale Road
Winnersh Triangle
RG41 5TU
United Kingdom
+44 (0)118 944 3300

Sponsor type




Funder type


Funder name

Emergent Product Development UK Ltd (UK) - commercially funded

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

06/05/2016: No publications found, verifying study status with principal investigator.